The Molecular Cloning of Artemisinic Aldehyde Δ11(13) Reductase and Its Role in Glandular Trichome-dependent Biosynthesis of Artemisinin in Artemisia annua
Abstract:At some point during biosynthesis of the antimalarial artemisinin in glandular trichomes of Artemisia annua, the ⌬11(13) double bond originating in amorpha-4,11-diene is reduced. This is thought to occur in artemisinic aldehyde, but other intermediates have been suggested. In an effort to understand double bond reduction in artemisinin biosynthesis, extracts of A. annua flower buds were investigated and found to contain artemisinic aldehyde ⌬11(13) double bond reductase activity. Through a combination of parti… Show more
“…Although the enzymatic steps involved in production of the nonphytotoxic precursors amorpha-4,11-diene (A-4,11-D) and dihydroartemisinic acid (DHAA) have been elucidated (12)(13)(14)(15) and the associated genes have been shown to be highly expressed in both the apical and subapical cells of the glandular secretory trichomes (3,16), the final steps in the conversion of DHAA to artemisinin are considered to be nonenzymatic and may be extracellular (17,18). Therefore, microbial-based "complete" synthetic biology routes to artemisinin may never be achievable.…”
Artemisinin, a sesquiterpene lactone produced by Artemisia annua glandular secretory trichomes, is the active ingredient in the most effective treatment for malaria currently available. We identified a mutation that disrupts the amorpha-4,11-diene C-12 oxidase (CYP71AV1) enzyme, responsible for a series of oxidation reactions in the artemisinin biosynthetic pathway. Detailed metabolic studies of cyp71av1-1 revealed that the consequence of blocking the artemisinin biosynthetic pathway is the redirection of sesquiterpene metabolism to a sesquiterpene epoxide, which we designate arteannuin X. This sesquiterpene approaches half the concentration observed for artemisinin in wild-type plants, demonstrating high-flux plasticity in A. annua glandular trichomes and their potential as factories for the production of novel alternate sesquiterpenes at commercially viable levels. Detailed metabolite profiling of leaf maturation time-series and precursor-feeding experiments revealed that nonenzymatic conversion steps are central to both artemisinin and arteannuin X biosynthesis. In particular, feeding studies using 13 C-labeled dihydroartemisinic acid (DHAA) provided strong evidence that the final steps in the synthesis of artemisinin are nonenzymatic in vivo. Our findings also suggest that the specialized subapical cavity of glandular secretory trichomes functions as a location for both the chemical conversion and the storage of phytotoxic compounds, including artemisinin. We conclude that metabolic engineering to produce high yields of novel secondary compounds such as sesquiterpenes is feasible in complex glandular trichomes. Such systems offer advantages over single-cell microbial hosts for production of toxic natural products.artemisinin | p450 oxidase | terpenoid | sesquiterpene | Artemisia annua
“…Although the enzymatic steps involved in production of the nonphytotoxic precursors amorpha-4,11-diene (A-4,11-D) and dihydroartemisinic acid (DHAA) have been elucidated (12)(13)(14)(15) and the associated genes have been shown to be highly expressed in both the apical and subapical cells of the glandular secretory trichomes (3,16), the final steps in the conversion of DHAA to artemisinin are considered to be nonenzymatic and may be extracellular (17,18). Therefore, microbial-based "complete" synthetic biology routes to artemisinin may never be achievable.…”
Artemisinin, a sesquiterpene lactone produced by Artemisia annua glandular secretory trichomes, is the active ingredient in the most effective treatment for malaria currently available. We identified a mutation that disrupts the amorpha-4,11-diene C-12 oxidase (CYP71AV1) enzyme, responsible for a series of oxidation reactions in the artemisinin biosynthetic pathway. Detailed metabolic studies of cyp71av1-1 revealed that the consequence of blocking the artemisinin biosynthetic pathway is the redirection of sesquiterpene metabolism to a sesquiterpene epoxide, which we designate arteannuin X. This sesquiterpene approaches half the concentration observed for artemisinin in wild-type plants, demonstrating high-flux plasticity in A. annua glandular trichomes and their potential as factories for the production of novel alternate sesquiterpenes at commercially viable levels. Detailed metabolite profiling of leaf maturation time-series and precursor-feeding experiments revealed that nonenzymatic conversion steps are central to both artemisinin and arteannuin X biosynthesis. In particular, feeding studies using 13 C-labeled dihydroartemisinic acid (DHAA) provided strong evidence that the final steps in the synthesis of artemisinin are nonenzymatic in vivo. Our findings also suggest that the specialized subapical cavity of glandular secretory trichomes functions as a location for both the chemical conversion and the storage of phytotoxic compounds, including artemisinin. We conclude that metabolic engineering to produce high yields of novel secondary compounds such as sesquiterpenes is feasible in complex glandular trichomes. Such systems offer advantages over single-cell microbial hosts for production of toxic natural products.artemisinin | p450 oxidase | terpenoid | sesquiterpene | Artemisia annua
“…The expression pattern matches the presence of ESTs corresponding to ADH2 from flower bud (AAFB), glandular trichome (AAGST), and "trichome-minus-bud" (GSTSUB) libraries (see 2.1). This expression pattern strongly suggests a role in terpenoid biosynthesis for ADH2 and has been seen for other enzymes proposed to have functions in trichome-specific terpenoid biosynthesis in A. annua (Teoh et al, 2009, Zhang et al, 2008.…”
Section: Tissue Specific Expression Analysis Of Adh2 In a Annuamentioning
confidence: 96%
“…The major components of A. annua essential oil are monoand sesquiterpenes (Ma et al, 2007), and they are thought to be biosynthesized within glandular trichomes (Duke et al, 1993, Olsson et al, 2009, Tellez et al, 1999. The sesquiterpenes in A. annua, in particular, the anti-malarial compound artemisinin and related compounds, have been studied extensively (Bertea et al, 2005, Covello et al, 2007, Ro et al, 2006, Teoh et al, 2006, Zhang et al, 2008. The proportion of the major essential oil components varies widely in different lines (or ecotypes) of A. annua.…”
Section: Introductionmentioning
confidence: 99%
“…annua (Covello et al, 2007, Covello, 2008, Teoh et al, 2009, Zhang et al, 2008. Indeed some of the largest contigs in the trichome-derived EST collection, i.e., the ones representing high expression, correspond to genes involved in isoprenoid biosynthesis (see Table 1).…”
The major components of the isoprenoid-rich essential oil of Artemisia annua L. accumulate in the subcuticular sac of glandular secretory trichomes. As part of an effort to understand isoprenoid biosynthesis in A. annua, an expressed sequence tags (EST) collection was investigated for evidence of genes encoding trichome-specific enzymes.This analysis revealed a gene denoted Adh2, that encodes an alcohol dehydrogenase and shows a high expression level in glandular trichomes relative to other tissues. The gene product, ADH2, shows up to 61% amino acid identity to members of the short chain alcohol dehydrogenase/reductase (SDR) superfamily, including Forsythia x intermedia secoisolariciresinol dehydrogenase (49.8% identity). Through in vitro biochemical analysis, ADH2 was found to show a strong preference for monoterpenoid secondary alcohols including carveol, borneol and artemisia alcohol. These results indicate a role for ADH2 in monoterpenoid ketone biosynthesis in A. annua glandular trichomes.
“…According to the reasonable extent of the artemisinin biosynthetic pathway that is known, more and more results point to dihydroartemisinic acid as the precursor of artemisinin. Therefore, artemisinic aldehyde reductase (DBR2) (Zhang et al, 2008), which catalyzes the conversion of artemisinic aldehyde to dihydroartemisinic aldehyde, and aldehyde dehydrogenase homologue (ALDH1) (Teoh et al, 2009), which converts dihydroartemisinic aldehyde to dihydryoartemisinic acid, seem more important in artemisinin biosynthesis. To increase artemisinin in A. annua, we believe that in co-overexpressing the combination of artemisinin biosynthesis genes, fps+dbr2, ads+dbr2, fps+aldh1, and ads+aldh1, for example, should be good candidates.…”
Section: Extraction and Analysis Of Artemisinin Content By Hplc-elsdmentioning
ABSTRACT.Finding an efficient and affordable treatment against malaria is still a challenge for medicine. Artemisinin is an effective antimalarial drug isolated from Artemisia annua. However, the artemisinin content of A. annua is very low. We used transgenic technology to increase the artemisinin content of A. annua by overexpressing cytochrome P450 monooxygenase (cyp71av1) and cytochrome P450 reductase (cpr) genes. CYP71AV1 is a key enzyme in the artemisinin biosynthesis pathway, while CPR is a redox partner for CYP71AV1. Eight independent transgenic A. annua plants were obtained through Agrobacterium tumefaciens-mediated transformation, which was confirmed by PCR and Southern blot analyses. The real-time qPCR results showed that the gene cyp71av1 was highly expressed at the transcriptional level in the transgenic A. annua plants. HPLC analysis showed that the artemisinin content was increased in a number of the transgenic plants, in which both cyp71av1 and cpr were overexpressed. In one of the transgenic A. annua plants, the artemisinin content was 38% higher than in the non-transgenic plants. We conclude that overexpressing key enzymes of the biosynthesis pathway is an effective means for increasing artemisinin content in plants.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.